{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-020969","form_type":"8-K","ticker":"ALKS","cik":"0001520262","company_name":"Alkermes plc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.959976+00:00","generated_at":"2026-06-22T13:38:42.305293+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Alkermes reports Q3 GAAP loss of $0.39/share; plans to separate oncology business","bullets":["Q3 total revenues $252.4M; net loss $64.0M; GAAP EPS -$0.39, non-GAAP EPS $0.02.","Proprietary product net sales $199.4M: VIVITROL $96.5M (+9% YoY), ARISTADA $75.7M (+10%), LYBALVI $27.1M.","Board approved exploration of separating oncology business into independent public company; expected completion H2 2023.","Updated FY2022 guidance: total revenue $1.07B-$1.12B, non-GAAP EPS $0.15-$0.33; LYBALVI outlook raised to $88-$95M.","One-time AMPYRA royalty reversal of ~$21.5M due to arbitration award."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-020969","json":"https://secwatch.observer/filing/0000950170-22-020969.json","markdown":"https://secwatch.observer/filing/0000950170-22-020969.md","text":"https://secwatch.observer/filing/0000950170-22-020969.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1520262/000095017022020969/0000950170-22-020969-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1520262/000095017022020969/alks-20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T13:38:42.305293+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"1dd25fea6812e3dec0550467a10313f50fdcae09","claim":"Alkermes plc. reported the third quarter of 2022 results: revenue $252.4 million, net income $64.0 million, EPS $0.39.","evidence_excerpt":"— Third Quarter Revenues of $252.4 Million Reflect Strong Year-Over-Year Growth of Proprietary Commercial Product Portfolio — — GAAP Loss per Share of $0.39 and Non-GAAP Earnings per Share of $0.02 —","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1520262/000095017022020969/0000950170-22-020969-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Revenue","value":"$252.4 million"},{"label":"Net income","value":"$64.0 million"},{"label":"EPS","value":"$0.39"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"8adbc0dce70ecb397ee878c962789c00dee8d434","claim":"Alkermes plc. reported the year ending December 31, 2022 results: revenue $1,070 – $1,120. Guidance raised.","evidence_excerpt":"to GAAP, except as otherwise noted. In millions (except per share amounts) Current 2022 Expectation (Provided 11/2/22) Prior 2022 Expectation (Provided 7/27/22) Total Revenue $1,070 – $1,120 $1,050 – $1,120 VIVITROL Net Sales $370 – $380 $365 – $385 ARISTADA Net Sales $300 – $310 $295 – $315 LYBALVI Net Sales $88 – $","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1520262/000095017022020969/0000950170-22-020969-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ending December 31, 2022"},{"label":"Revenue","value":"$1,070 – $1,120"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}